Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H16ClN3O3S |
Molecular Weight | 365.835 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1NC2=CC(Cl)=C(C=C2C(=O)N1C3=C(C)C=CC=C3)S(N)(=O)=O
InChI
InChIKey=AQCHWTWZEMGIFD-UHFFFAOYSA-N
InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
Metolazone is a thiazide-like diuretic marketed under the brand names Mykrox and Zaroxolyn. Zaroxolyn is indicated for the treatment of salt and water retention including:
• Edema accompanying congestive heart failure;
• Edema accompanying renal diseases including the
nephrotic syndrome and states of diminished renal
function.
Zaroxolyn is also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. The actions of Metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. A proximal action of Metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.
Originator
Sources: http://www.centaurpharma.com/pdf/news/metolaz-scrip.pdf | http://www.everydayhealth.com/drugs/metolazone
Curator's Comment: Metolazone was developed in the 1970s by an Indian-born chemist named Dr. Bola Vithal Shetty.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZAROXOLYN Approved UseMetolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox® tablets are to be substituted for Zaroxolyn® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequence of pregnancy. Metolazone tablets USP are indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see PRECAUTIONS). Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate. Launch Date1.23206402E11 |
|||
Primary | ZAROXOLYN Approved UseMetolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox® tablets are to be substituted for Zaroxolyn® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequence of pregnancy. Metolazone tablets USP are indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see PRECAUTIONS). Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate. Launch Date1.23206402E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.225 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29145890 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
METOLAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.63 ng/mL DRUG LABEL http://products.sanofi.ca/en/zaroxolyn.pdf |
2.5 mg 1 times / day unknown, oral dose: 2.5 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
METOLAZONE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
50.51 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29145890 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
METOLAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
99.74 ng × h/mL DRUG LABEL http://products.sanofi.ca/en/zaroxolyn.pdf |
2.5 mg 1 times / day unknown, oral dose: 2.5 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
METOLAZONE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.47 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29145890 |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
METOLAZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.5% DRUG LABEL http://products.sanofi.ca/en/zaroxolyn.pdf |
2.5 mg 1 times / day unknown, oral dose: 2.5 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
METOLAZONE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
150 mg single, oral Highest studied dose Dose: 150 mg Route: oral Route: single Dose: 150 mg Sources: Page: p.197 |
unhealthy, 18, 19 n = 2 Health Status: unhealthy Condition: Chronic renal failure Age Group: 18, 19 Sex: M+F Population Size: 2 Sources: Page: p.197 |
|
20 mg 1 times / day multiple, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Edema Sources: |
Disc. AE: Hyponatremia, Hypokalemia... AEs leading to discontinuation/dose reduction: Hyponatremia (severe) Sources: Hypokalemia (severe) |
20 mg 1 times / day multiple, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Edema Sources: Page: p.3 |
Disc. AE: Azotemia, Hyperuricemia... AEs leading to discontinuation/dose reduction: Azotemia Sources: Page: p.3Hyperuricemia |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypokalemia | severe Disc. AE |
20 mg 1 times / day multiple, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Edema Sources: |
Hyponatremia | severe Disc. AE |
20 mg 1 times / day multiple, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Edema Sources: |
Azotemia | Disc. AE | 20 mg 1 times / day multiple, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Edema Sources: Page: p.3 |
Hyperuricemia | Disc. AE | 20 mg 1 times / day multiple, oral (max) Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Edema Sources: Page: p.3 |
PubMed
Title | Date | PubMed |
---|---|---|
Severe electrolyte disturbances associated with metolazone and furosemide. | 1978 Apr |
|
Hypoplastic anemia associated with metolazone. | 1979 Jul 13 |
|
Palpable acute necrotizing arteritis secondary to metolazone. | 1982 Jul |
|
Excessive potassium depletion with metolazone and furosemide. | 1983 Jul-Aug |
|
Use of a bioassay in healthy men to evaluate diuretic-spironolactone combinations. | 1983 May |
|
Vasculitis due to metolazone. | 1991 Sep |
|
Metolazone-induced cholestatic liver disease. | 2001 Aug-Sep |
|
Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. | 2001 Jan |
|
Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. | 2002 |
|
Risk factors for the development and progression of dyslipidemia after heart transplantation. | 2002 Apr 27 |
|
Diuretic resistance predicts mortality in patients with advanced heart failure. | 2002 Jul |
|
Functional expression of mutations in the human NaCl cotransporter: evidence for impaired routing mechanisms in Gitelman's syndrome. | 2002 Jun |
|
Determination of a Metolazone metabolite in human urine by high-performance liquid chromatography/diode-array detection, high-performance liquid chromatography/electrospray ionization mass spectrometry and gas chromatography/mass spectrometry. | 2004 |
|
Pathophysiology of functional mutations of the thiazide-sensitive Na-Cl cotransporter in Gitelman disease. | 2004 Aug |
|
FI-chemiluminometric study of thiazides by on-line photochemical reaction. | 2004 Nov 19 |
|
[The place of diuretics in the treatment of chronic heart failure. Part I]. | 2005 |
|
Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation. | 2005 Aug |
|
[Diuretic therapy in heart failure]. | 2006 Jan-Feb |
|
Cardiomyopathy, familial dilated. | 2006 Jul 13 |
|
The evaluation of the diuretic action of parenteral formulations of metolazone. | 2007 Jan-Feb |
|
Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. | 2007 May |
|
Premenstrual syndrome. | 2007 May 1 |
|
Vitamin C-induced hyperoxaluria causing reversible tubulointerstitial nephritis and chronic renal failure: a case report. | 2007 Nov 27 |
|
Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. | 2008 |
|
The renal cortical interstitium: morphological and functional aspects. | 2008 Aug |
|
Acute right ventricular failure in the setting of acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and management. | 2008 Feb |
|
Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications? | 2008 Jul 21 |
|
Non-healing painful ulcers in a patient with chronic kidney disease and role of sodium thiosulfate: a case report. | 2008 Sep 23 |
|
How to use diuretics in heart failure. | 2009 Dec |
|
[Renal effect of treatment for heart failure]. | 2009 Feb 23 |
|
Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. | 2009 Jan-Feb |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Characterizing environmental and phenotypic associations using information theory and electronic health records. | 2009 Sep 17 |
|
Advances in systolic heart failure. | 2010 Apr 27 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. | 2010 Dec 3 |
|
Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. | 2010 Nov 2 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/metolazone.html
Usual Adult Dose for Hypertension
Initial dose: 2.5 mg orally once a day (Zaroxolyn) or
0.5 mg orally once a day (Mykrox).
Usual Adult Dose for Edema
Initial dose: 5 mg orally once a day (Zaroxolyn) or
0.5 mg orally once a day (Mykrox).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9011622
In flounder bladder, metolazone (100 uM) is the most potent
of the thiazide diuretics, inhibiting 22Na+ uptake by
Na+-Cl- cotransport by ~90%
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
630
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
||
|
WHO-ATC |
C03BA08
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
||
|
WHO-VATC |
QC03BA08
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
||
|
NDF-RT |
N0000175359
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
||
|
WHO-ATC |
C03EA12
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
||
|
NCI_THESAURUS |
C49185
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
||
|
WHO-VATC |
QC03EA12
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
||
|
NDF-RT |
N0000175420
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000080921
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
METOLAZONE
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
SUB08906MIG
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
CHEMBL878
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
DTXSID6045167
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
TZ7V40X7VX
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
3367
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
1783
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
Metolazone
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
2627
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
64354
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
241-539-3
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
TZ7V40X7VX
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
4838
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
17560-51-9
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
759581
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
C650
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
m7494
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | Merck Index | ||
|
1441200
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
4170
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
6916
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB00524
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY | |||
|
D008788
Created by
admin on Fri Dec 15 15:43:13 UTC 2023 , Edited by admin on Fri Dec 15 15:43:13 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)